| Date | Time | Source | Headline | Symbol | Company |
| 03/01/2021 | 10:00AM | PR Newswire (US) | Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 03/01/2021 | 5:00AM | PR Newswire (US) | Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 01/06/2021 | 1:00PM | Business Wire | Global Coalition for Adaptive Research, Kazia, & Kintara Announce Commencement of Kazia’s Paxalisib & Kintara’s VAL-083 i... | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 01/04/2021 | 6:23AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/17/2020 | 6:10AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/14/2020 | 6:10AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/10/2020 | 10:00AM | PR Newswire (US) | Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/09/2020 | 10:30AM | PR Newswire (US) | Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/18/2020 | 6:07AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/17/2020 | 5:47PM | PR Newswire (US) | Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/10/2020 | 6:10AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/06/2020 | 6:10AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/06/2020 | 6:10AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 10/30/2020 | 6:09AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 10/16/2020 | 10:30AM | PR Newswire (US) | Kazia Executes Agreement To Commence GBM Agile Pivotal Study | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 10/16/2020 | 5:30AM | PR Newswire (US) | Kazia Executes Agreement To Commence GBM Agile Pivotal Study | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 09/22/2020 | 10:00AM | PR Newswire (US) | Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 09/22/2020 | 6:04AM | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 09/18/2020 | 6:10AM | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 09/15/2020 | 5:21PM | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 08/24/2020 | 6:10AM | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 08/24/2020 | 5:30AM | PR Newswire (US) | US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 08/23/2020 | 8:30PM | PR Newswire (US) | US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 08/20/2020 | 10:30AM | PR Newswire (US) | US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 08/20/2020 | 6:03AM | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 08/20/2020 | 5:30AM | PR Newswire (US) | US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 08/07/2020 | 10:30AM | PR Newswire (US) | US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 08/07/2020 | 6:12AM | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 08/07/2020 | 5:30AM | PR Newswire (US) | US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 06/22/2020 | 10:30AM | PR Newswire (US) | Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs | NASDAQ:KZIA | Kazia Therapeutics Ltd |